Pediatrix Medical Group, Inc. (MD)
| Market Cap | 1.89B +58.5% |
| Revenue (ttm) | 1.93B -2.3% |
| Net Income | 174.22M |
| EPS | 2.06 |
| Shares Out | 80.19M |
| PE Ratio | 11.44 |
| Forward PE | 10.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,146,163 |
| Open | 23.65 |
| Previous Close | 23.55 |
| Day's Range | 22.91 - 23.73 |
| 52-Week Range | 11.84 - 24.99 |
| Beta | 0.70 |
| Analysts | Buy |
| Price Target | 23.17 (-1.86%) |
| Earnings Date | Aug 4, 2026 |
About MD
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fe... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for MD stock is "Buy." The 12-month stock price target is $23.17, which is a decrease of -1.86% from the latest price.
News
New Anglia University Responds to Rising Competition for Medical School Places in the UK
George Hill, Anguilla, 17 June 2026 -- As competition for medical school places in the United Kingdom reaches unprecedented levels, New Anglia University is providing aspiring doctors with an alternat...
Onera Will Showcase Its Onera hPSG® Solution at the SLEEP 2026 Conference June 14-17, 2026 in Baltimore, MD, USA.
EINDHOVEN, Netherlands--(BUSINESS WIRE)-- #MedicalDevice--Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, ...
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake R...
Pediatrix Medical announces publication of research on NEC in preterm infants
Pediatrix Medical (MD) Group announced the publication of new research on probiotic use and necrotizing enterocolitis in preterm infants, addressing pressing questions about one of the most controvers...
Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology.
HSS Chief of Sports Medicine, Riley J. Williams III, MD, Named FIFA Venue Medical Officer for the 2026 World Cup
NEW YORK--(BUSINESS WIRE)--FIFA World Cup 26™ has named Hospital for Special Surgery (HSS), ranked No. 1 in orthopedics nationally by U.S. News & World Report (2024–2025), Sports Medicine Surgeon, Ril...
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Passkey Therapeutics Appoints Mandeep Kaur, MD, MS, as Chief Medical Officer to Advance Clinical Validation of Its Computational Genetics-Based Novel Drug Combination Platform
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Passkey Therapeutics, the architect of the Locksmith® platform for systematically identifying new therapeutic opportunities from synergistic drug combinations, today...
Pediatrix Medical price target raised to $25 from $22 at UBS
UBS raised the firm’s price target on Pediatrix Medical (MD) to $25 from $22 and keeps a Neutral rating on the shares.
Pediatrix Medical price target raised to $24 from $21 at Mizuho
Mizuho raised the firm’s price target on Pediatrix Medical (MD) to $24 from $21 and keeps a Neutral rating on the shares.
Pediatrix Medical Group Earnings Call Transcript: Q1 2026
Q1 delivered strong adjusted EBITDA of $58M, driven by 4% pricing growth and favorable payer mix, offsetting modest volume declines. Full-year adjusted EBITDA guidance of $280M–$300M is reaffirmed, with pricing expected to remain flat as RCM cash collection impact tapers.
Pediatrix Medical Group Quarterly report: Q1 2026
Pediatrix Medical Group has published its Q1 2026 quarterly earnings report on May 5, 2026.
Pediatrix Medical Group Earnings release: Q1 2026
Pediatrix Medical Group released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Pediatrix Medical reaffirms FY26 adjusted EBITDA view $280M-$300M
06:10 EDT Pediatrix Medical (MD) reaffirms FY26 adjusted EBITDA view $280M-$300M
Pediatrix Medical Group Reports First Quarter Results
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Reports First Quarter Results.
Ambience Healthcare Appoints Michael Han, MD, MBA as Chief Medical Officer
SAN FRANCISCO--(BUSINESS WIRE)--Ambience Healthcare, the leading AI platform for clinical documentation and revenue integrity, today announced the appointment of Michael Han, MD, MBA as Chief Medical ...
Pediatrix Medical price target raised to $27 from $24 at Jefferies
Jefferies analyst Jack Slevin raised the firm’s price target on Pediatrix Medical (MD) to $27 from $24 and keeps a Buy rating on the shares. The relative underperformance of healthcare…
Pediatrix Medical Group 2026 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 5, 2026
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group 2026 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 5, 2026.
Pediatrix Medical Group Proxy statement: Proxy filing
Pediatrix Medical Group filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Pediatrix Medical price target raised to $23 from $21 at Truist
Truist raised the firm’s price target on Pediatrix Medical (MD) to $23 from $21 and keeps a Hold rating on the shares as part of a broader research note previewing…
Pediatrix Medical Group Proxy statement: Proxy filing
Pediatrix Medical Group filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Pediatrix Medical Group Proxy statement: Proxy filing
Pediatrix Medical Group filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine.
Pediatrix Welcomes Two Nationally Renowned Physician Leaders
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Welcomes Two Nationally Renowned Physician Leaders.
Pediatrix Medical price target lowered to $22 from $23 at UBS
UBS analyst AJ Rice lowered the firm’s price target on Pediatrix Medical (MD) to $22 from $23 and keeps a Neutral rating on the shares. The ACA headwind remains a…